• Home
  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Cardiology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma News
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Subscribe
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma News

BioPharma News

Biopharmaceutical industry analysis. Credible, reliable, equitable.

Subscribe
  • Home
  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Cardiology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma News
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Subscribe

Novartis

Posted inCardiology, Metabolism, New Drugs, Rare/Orphan Diseases, Regulatory

Leqvio: Newest Drug Against ‘Very Bad’ Cholesterol

by Mark Gubar December 23, 2021April 5, 2024

Two injections of inclisiran a year and you can forget about high cholesterol. Novartis doesn’t lie.

asthma
Posted inAutoimmune Diseases, New Drugs, Regulatory

Tezspire: Effective Treatment for Severe Uncontrolled Asthma

by Mark Gubar December 19, 2021September 8, 2022

Tezepelumab is a powerful new drug for asthma, invented by Amgen and AstraZeneca, with a completely new mechanism of action.

coronavirus
Posted inCOVID-19, Infections, Research

Omicron Variant: Latest Scientific News, Findings, Evidence, and Developments

by Nik Resovski and Timur Burkhanayev December 17, 2021April 11, 2024

Up-to-date scientific information about the new Omicron variant of SARS-CoV-2/COVID-19.

Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory

Kesimpta: Highly Effective New Drug for Multiple Sclerosis

by Julia Mardi June 4, 2021September 8, 2022

Ofatumumab by Novartis is as good and convenient as Ocrevus by Roche against multiple sclerosis.

Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory

Ponvory: Another Drug for Multiple Sclerosis

by Mark Gubar May 17, 2021September 8, 2022

Ponesimod is a new drug that changes the course of multiple sclerosis and is a direct competitor to Gilenya (fingolimod), Mayzent (siponimod), and Zeposia (ozanimod).

Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory

Zeposia: New Drug to Treat Relapsing Multiple Sclerosis

by Julia Mardi April 21, 2021September 8, 2022

Bristol-Myers Squibb has come up with ozanimod, a direct competitor to Novartis’ fingolimod and siponimod, for the treatment of multiple sclerosis.

Posted inNeuroscience, New Drugs, Rare/Orphan Diseases, Regulatory

Zolgensma: Gene Therapy That Cure Spinal Muscular Atrophy. The Most Comprehensive Review

by Tanya von Reuss, Mark Gubar, Alex Avisoni and Nik Resovski April 8, 2021September 8, 2022

Novartis revealed the most expensive drug in the world. And it is amazing.

Posts pagination

Newer posts 1 2 3 4 Older posts
BioPharma News Logo
Biopharmaceutical industry analysis.
© 2025 BioPharma News Powered by Newspack Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma News

Awareness and enlightenment are strengths.

BioPharma News is an amazing and trustworthy non-profit data analysis service that provides honest and objective reporting on the Pharma & Biotech industry. We would like to invite you to sign up for our weekly Newsletter to stay informed and uptodate.

Please check your inbox or spam folder for an email from [email protected] to confirm your subscription.

×